WEKO3
アイテム
HER2高発現胃がん肝転移に対する新規アルファ線放射免疫療法
https://repo.qst.go.jp/records/77294
https://repo.qst.go.jp/records/772944fc9a11c-98c4-412e-9a9c-ac171b0e44d6
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2019-11-05 | |||||
| タイトル | ||||||
| タイトル | HER2高発現胃がん肝転移に対する新規アルファ線放射免疫療法 | |||||
| 言語 | ||||||
| 言語 | jpn | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
李, 惠子
× 李, 惠子× 長谷川, 純崇× Li, Huizi× Hasegawa, Sumitaka |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Gastric cancer (GC) patients often already have distant metastasis at the time of diagnosis, and 4-14% of them are liver metastasis (LMGC) with dismal prognosis. Trastuzumab, a humanized anti-HER2 monoclonal antibody, is clinically used for the treatment of HER2-positive (HER2+) GC, which account for about 20% of GC. Alpha-radioimmunotherapy (α-RIT) is getting higher attention as a novel therapeutic option for metastasis, benefited from the combination of advantages of antibodies, cancer specific targeting, and alpha particles, high cell killing effects and short range. Astatine 211 (211At) is one of the attractiveα-emitter for clinical use. In this study, we investigated the therapeutic efficacy and toxicity using preclinical HER2+ LMGC mice model and provided the proof of concept thatα-RIT with 211At-trastuzumab has high potential as a novel therapeutic option against HER2+ LMGC. |
|||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 第59回日本核医学会学術総会 | |||||
| 発表年月日 | ||||||
| 日付 | 2019-11-02 | |||||
| 日付タイプ | Issued | |||||
